We are experiencing some temporary issues. The market data on this page are currently delayed. Please bear with us as we address this and restore your personalized lists.

Canada markets close in 3 hours 37 minutes

Sirona Biochem Corp. (SBM.V)

TSXV - TSXV Real Time Price. Currency in CAD
Add to watchlist
0.23000.0000 (0.00%)
As of 3:04PM EDT. Market open.
Full screen
Previous Close0.2300
Bid0.2100 x 0
Ask0.2300 x 0
Day's Range0.2150 - 0.2300
52 Week Range0.1800 - 0.5300
Avg. Volume69,545
Market Cap52.051M
Beta (5Y Monthly)0.18
PE Ratio (TTM)N/A
EPS (TTM)-0.0230
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateDec. 27, 2006
1y Target EstN/A
  • /R E P E A T -- Sirona Biochem Ships First Batch of TFC-1067 to Rodan + Fields/
    CNW Group

    /R E P E A T -- Sirona Biochem Ships First Batch of TFC-1067 to Rodan + Fields/

    Using the services and expertise of Contract Research Organization, Roowin SA, Sirona scaled-up production to the multi-kilogram level. Sirona management is currently in advanced negotiations with Chinese producers regarding large scale manufacturing of TFC-1067 and expects to sign an agreement in this regard within the next quarter. Sirona also announces a successful attendance at BIO Digital, June 8-12, 2020.

  • CNW Group

    /R E P E A T -- Sirona Biochem: Interview with Chief Scientific Officer Dr. Deliencourt-Godefroy on the Development Pipeline/

    Other projects at early stages of research and development include therapeutic compounds to treat urinary tract infections, Crohn's disease, anti-inflammatory drugs and anticancer drugs are now made public. "The anti-wrinkle program is progressing nicely with further studies beginning next week and the potential for a clinical trial in 2021", added Dr. Howard Verrico , CEO of Sirona Biochem.

  • CNW Group

    /R E P E A T -- Sirona Biochem Initiates COVID-19 and Infectious Diseases Development Program/

    After two months of extensive research, TFChem scientists have determined the proprietary platform technology can be applied to develop new antiviral compounds. The goal is to develop novel multi-target antiviral compounds, affecting different steps of the viral life cycle. Therapies to treat most viral infections are limited and the emergence of new viruses can greatly endanger society, as is currently the case with the pandemic caused by COVID-19, also known as Coronavirus or SARS-CoV-2.

  • /R E P E A T -- Sirona Biochem: Letter to the Shareholders/
    CNW Group

    /R E P E A T -- Sirona Biochem: Letter to the Shareholders/

    Over the last several weeks, Sirona Biochem's management has been monitoring the recent increase in cases of Coronavirus (COVID-19), as we are sure many of you have. As an international organization, operating on three continents, Sirona has been one of the many companies affected by recent events.

  • CNW Group

    /R E P E A T -- Sirona Biochem Signs Letter of Intent with Top Chinese Pharmaceutical Development Company/

    Huaxipharm will co-develop on all steps to complete full commercialization of the products created by Sirona. This includes preclinical, clinical development, regulatory, commercial scale up and manufacturing for commercial applications of Sirona's compounds for indications mutually agreed upon in the definitive agreement.

  • Did Business Growth Power Sirona Biochem's (CVE:SBM) Share Price Gain of 208%?
    Simply Wall St.

    Did Business Growth Power Sirona Biochem's (CVE:SBM) Share Price Gain of 208%?

    It might be of some concern to shareholders to see the Sirona Biochem Corp. (CVE:SBM) share price down 17% in the last...

  • Sirona Biochem Announces Change of Auditor
    CNW Group

    Sirona Biochem Announces Change of Auditor

    VANCOUVER , Feb. 14, 2020 /CNW/ - Sirona Biochem Corp. (SBM.V) (ZSB.F) (SRBCF) (the "Company") announces that it has changed its auditors from MNP LLP (the "Former Auditor") to DeVisser Gray LLP (the "Successor Auditor") effective January 27, 2020 and the board of directors of the Company appointed the Successor Auditor as the Company's auditor effective January 27, 2020 until the next Annual General Meeting of the Company. There were no reservations in the Former Auditor's audit reports for the relevant period, being the financial years ended October 31, 2018 and October 31, 2017 and any period subsequent to the most recently completed financial year for which an audit report was issued and preceding the resignation of the Former Auditor.

  • Baystreet

    Stocks in play: Sirona Biochem Corp.

    Announced that the final toxicology test, a Human Repeated Insult Patch Test, has successfully been ...

  • CNW Group

    /R E P E A T -- Sirona Biochem: 100% Safety in Final Tox Study for Increased Concentration of TFC-1067/

    Sirona is now in preparation for the increased dose (0.4%) clinical study for its skin lightening compound TFC-1067. The HRIPT study was coordinated by Eurofins Dermscan in Poland (www.eurofins.com) and was executed by Eurofins EVIC Product Testing Romania under the direction of a clinical dermatologist.

  • Sirona Biochem Announces Grant of Stock Options
    CNW Group

    Sirona Biochem Announces Grant of Stock Options

    The options, to purchase common shares in the capital of the Company at a price of $0.45 per common share, will be for periods ranging from 1 to 10 years. The options have been granted under the terms of the Company's stock option plan. Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology.